Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia

PURPOSE: To date, litte evidence is reported about the real-life dosage of tyrosine kinase inhibitors prescribed in Italy. The present observational retrospective study aimed to evaluate the mean daily dose of nilotinib prescribed as first- and second-line therapy among patients suffering from chron...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Valentina, Giacomini, Elisa, Andretta, Margherita, Arenare, Loredana, Cillo, Maria Rosaria, Latini, Marisa, Mecozzi, Alessandra, Pagliaro, Romina, Vercellone, Adriano, Degli Esposti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197625/
https://www.ncbi.nlm.nih.gov/pubmed/34135589
http://dx.doi.org/10.2147/TCRM.S309342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197625/
https://www.ncbi.nlm.nih.gov/pubmed/34135589
http://dx.doi.org/10.2147/TCRM.S309342

Ejemplares similares